x

Search for a networks

* (*) mandatory field

A phase Ia/II multicenter, dose-escalation study of oral AMN107 on a continuous daily dosing schedule in adult patients with imatinib-resistant/intolerant CML in chronic or accelerated phase or blast crisis, relapsed/refractory Ph+ALL, and other hematologic malignancies (coordination)

  • Type of network : Multinational clinical trials
  • Geographic coverage : Global
  • Funding body(ies) : -
  • Sponsor : Novartis international ag
  • Website
  • Coordinator of multinational clinical trial

  • NOVARTIS INTERNATIONAL AG
  • Novartis International AG
  • WSJ-103.4.26
  • 4002 BASEL
  • SWITZERLAND
  • More information
  • Phone  : 0041 (0)61 324 1111
  • Fax  : 0041 (0)61 324 8001
Last update: July 2011

Additional information

The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.